Systemic administration of an Fcγ-Fcε-fusion protein in house dust mite sensitive nonhuman primates

Clinical Immunology

Volumn 128, Issue 3, 2008, Pages 340-348

  Van Scott, Michael R ^a   Mertsching, Elisabeth ^b   Negrou, Ella ^b   Miles, Jeremy ^a   Stallings III, Howard W ^a   Graff, Candace ^b   Kehry, Marilyn R ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b BIOGEN   (United States)

Author keywords

Allergy; Asthma; Basophils; Chimeric protein; Early asthmatic response; GE2; Mast cells

Indexed keywords

CHIMERIC PROTEIN; FC RECEPTOR; HISTAMINE; HOUSE DUST ALLERGEN; HYBRID PROTEIN; IMMUNOGLOBULIN E; PROTEIN HGE2; ALLERGEN; FCGR2B PROTEIN, HUMAN; IMMUNOGLOBULIN E RECEPTOR;

ADOLESCENT; ALLERGIC ASTHMA; ALLERGIC REACTION; ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BASOPHIL; CROSS LINKING; DERMATOPHAGOIDES; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FACE EDEMA; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LETHARGY; LUNG FUNCTION; MACACA; MALE; MAST CELL; MAST CELL DEGRANULATION; MAXIMUM PLASMA CONCENTRATION; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; VOMITING; ANIMAL; ASTHMA; IMMUNOLOGY; METABOLISM; PYROGLYPHIDAE;

ALLERGENS; ANIMALS; ASTHMA; BASOPHILS; HISTAMINE RELEASE; HUMANS; MACACA FASCICULARIS; MALE; MAST CELLS; PYROGLYPHIDAE; RECEPTORS, IGE; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS;

EID: 49149116126     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.05.001     Document Type: Article

References (20)

1. Lilly C.M. Diversity of asthma: evolving concepts of pathophysiology and lessons from genetics. J. Allergy Clin. Immunol. 115 (2005) S526-S531
2. Kinet J.P. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu. Rev. Immunol. 17 (1999) 931-972
3. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M., and Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23 (2005) 749-786
4. Kubo S., Nakayama T., Matsuoka K., Yonekawa H., and Karasuyama H. Long term maintenance of IgE-mediated memory in mast cells in the absence of detectable serum IgE. J. Immunol. 170 (2003) 775-780
5. Kraft S., and Novak N. Fc receptors as determinants of allergic reactions. Trends Immunol. 27 (2006) 88-95
6. Katz H.R. Inhibitory receptors and allergy. Curr. Opin. Immunol. 14 (2002) 698-704
7. Noon L. Prophylactic inoculation against hay fever. Lancet 1 (1911) 1572-1573
8. Freeman J. Vaccination against hay fever: report of results during the first three years. Lancet 1 (1914) 1178-1180
9. Zhu D., Kepley C.L., Zhang M., Zhang K., and Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat. Med. 8 (2002) 518-521
10. Yamada T., Zhu D., Zhang K., and Saxon A. Inhibition of interleukin-4-induced class switch recombination by a human immunoglobulin Fc gamma-Fc epsilon chimeric protein. J. Biol. Chem. 278 (2003) 32818-32824
11. Zhang K., Kepley C.L., Terada T., Zhu D., Perez H., and Saxon A. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J. Allergy Clin. Immunol. 114 (2004) 321-327
12. Van Scott M.R., Hooker J.L., Ehrmann D., Shibata Y., Kukoly C., Salleng K., Westergaard G., Sandrasagra A., and Nyce J. Dust mite-induced asthma in cynomolgus monkeys. J. Appl. Physiol. 96 (2004) 1433-1444
13. Van Scott M.R., Aycock D., Cozzi E., Salleng K., and Stallings H.W. Separation of bronchoconstriction from increased ventilatory drive in a nonhuman primate model of chronic allergic asthma. J. Appl. Physiol. 99 (2005) 2080-2086
14. Saxon A., Zhu D., Zhang K., Allen L.C., and Kepley C.L. Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases. Curr. Opin. Allergy Clin. Immunol. 4 (2004) 563-568
15. Mertsching E., Bafetti L., Hess H., Perper S., Giza K., Allen L.C., Negrou E., Hathaway K., Hopp J., Chung J., Perret D., Shields M., Saxon A., and Kehry M.R. A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases. J. Allergy Clin. Immunol. 121 2 (2008) 441-447
16. Shankar G., Pendley C., and Stein K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25 5 (2007) 555-561
17. Bugelski P.J., and Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. 6 1 (2004) 10-16
18. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276 9 (2001) 6591-6604
19. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20 Suppl 6 (2005) vi3-vi9
20. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1 (2002) 457-462